Skip to main content
    R

    ResMed Inc (RMD)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $238.23
    -1.30 (-0.54%)

    Market Cap: $33.69B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    ResMed Inc (RMD) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    ResMed (RMD) is expected to report earnings on Jan 27, 2027. In the quarter ended Sep 30, 2026, ResMed reported EPS of $2.91, above the $2.67 estimate. It beat the EPS estimate in each of the last 13 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    88%(35/40)
    Avg Surprise
    +5.65%
    Streak
    13 Q

    Upcoming Estimates

    Reports Jan 27, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.99
    Range$2.93 - $3.13
    13 analysts
    EPS Revisions
    1
    6
    30d
    EPS Estimate DriftChange to current
    90d ago$3.01-0.8%
    60d ago$3.04-1.5%
    30d ago$3.03-1.4%
    7d ago$3.02-1.1%
    Current$2.99
    Revenue Consensus
    $1.46B
    Range$1.45B - $1.48B
    15 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$3.06
    Range$3.02 - $3.10
    13 analysts
    EPS Revisions
    0
    13
    30d
    EPS Estimate DriftChange to current
    90d ago$3.04+0.4%
    60d ago$3.14-2.6%
    30d ago$3.15-2.9%
    7d ago$3.14-2.8%
    Current$3.06
    Revenue Consensus
    $1.46B
    Range$1.44B - $1.48B
    15 analysts

    Next Report

    RMD has an expected report date of Jan 27, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 6.4% above the $2.81 reported for the quarter ended Dec 31, 2025.

    RMD Earnings Call

    The latest RMD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, RMD beat 35, missed 4 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $1.41B, up 5.2% from $1.34B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.91$2.67$2.62 - $2.76+8.99%Beat+14.1%130 up, 1 downOct 29, 2026$1.41B
    Jun 30, 2026$2.95$2.90$2.78 - $2.98+1.72%Beat+15.7%90 up, 1 downAug 6, 2026$1.46B
    Mar 31, 2026$2.86$2.80$2.72 - $2.85+2.14%Beat+20.7%131 up, 2 downApr 30, 2026$1.43B
    Dec 31, 2025$2.81$2.72$2.63 - $2.87+3.31%Beat+15.6%141 up, 0 downJan 29, 2026$1.42B
    Sep 30, 2025$2.55$2.50$2.45 - $2.56+2.00%Beat+15.9%120 up, 0 downOct 30, 2025$1.34B
    Jun 30, 2025$2.55$2.48$2.35 - $2.60+2.82%Beat+22.6%13N/AJul 31, 2025$1.35B
    Mar 31, 2025$2.37$2.36$2.32 - $2.41+0.42%Beat+11.3%123 up, 6 downApr 23, 2025$1.29B
    Dec 31, 2024$2.43$2.31$2.26 - $2.38+5.19%Beat+29.3%130 up, 1 downJan 30, 2025$1.28B
    Sep 30, 2024$2.20$2.04$1.99 - $2.12+7.84%Beat+34.1%81 up, 0 downOct 24, 2024$1.22B
    Jun 30, 2024$2.08$2.07$1.95 - $2.18+0.48%Beat+30.0%110 up, 0 downAug 1, 2024$1.22B
    Mar 31, 2024$2.13$1.91$1.81 - $1.99+11.52%Beat+26.8%101 up, 0 downApr 25, 2024$1.20B
    Dec 31, 2023$1.88$1.78$1.68 - $1.90+5.62%Beat+13.3%91 up, 0 downJan 24, 2024$1.16B
    Sep 30, 2023$1.64$1.61$1.55 - $1.68+1.86%Beat+8.6%90 up, 2 downOct 26, 2023$1.10B
    Jun 30, 2023$1.60$1.69$1.60 - $1.73-5.33%Miss+7.4%100 up, 1 downAug 3, 2023$1.12B
    Mar 31, 2023$1.68$1.59$1.53 - $1.65+5.66%Beat+27.3%91 up, 1 downApr 27, 2023$1.12B
    Dec 31, 2022$1.66$1.62$1.57 - $1.72+2.47%Beat+12.9%90 up, 0 downJan 26, 2023$1.03B
    Sep 30, 2022$1.51$1.60N/A-5.63%Miss0.0%60 up, 0 downOct 27, 2022$950.29M
    Jun 30, 2022$1.49$1.46N/A+2.05%Beat+10.4%N/A0 up, 0 downAug 11, 2022$914.74M
    Mar 31, 2022$1.32$1.44$1.39 - $1.47-8.33%Miss+1.5%60 up, 0 downApr 28, 2022$864.50M
    Dec 31, 2021$1.47$1.52$1.42 - $1.60-3.29%Miss+4.3%51 up, 0 downJan 27, 2022$894.87M
    Sep 30, 2021$1.51$1.35$1.24 - $1.52+11.85%Beat+18.9%63 up, 0 downOct 28, 2021$904.01M
    Jun 30, 2021$1.35$1.29$1.24 - $1.46+4.65%Beat+1.5%8N/AAug 5, 2021$876.10M
    Mar 31, 2021$1.30$1.27$1.08 - $1.38+2.36%Beat+0.8%8N/AApr 29, 2021$768.77M
    Dec 31, 2020$1.41$1.28$1.18 - $1.37+10.16%Beat+16.5%8N/AJan 28, 2021$800.01M
    Sep 30, 2020$1.27$1.03$0.93 - $1.17+23.30%Beat+36.6%8N/AOct 29, 2020$751.94M
    Jun 30, 2020$1.33$1.07$0.75 - $1.33+24.30%Beat+40.0%8N/AAug 5, 2020$770.35M
    Mar 31, 2020$1.29$1.08$0.87 - $1.17+19.44%Beat+44.9%8N/AApr 30, 2020$769.46M
    Dec 31, 2019$1.21$1.02$0.96 - $1.08+18.63%Beat+21.0%8N/AJan 30, 2020$736.16M
    Sep 30, 2019$0.93$0.87$0.76 - $0.98+6.90%Beat+14.8%7N/AOct 24, 2019$681.06M
    Jun 30, 2019$0.95$0.92$0.88 - $1.03+3.26%Beat0.0%7N/AJul 25, 2019$704.94M
    Mar 31, 2019$0.89$0.85$0.79 - $0.95+4.71%Beat-3.3%8N/AMay 2, 2019$662.23M
    Dec 31, 2018$1.00$0.95$0.89 - $0.97+5.26%Beat0.0%7N/AJan 24, 2019$651.10M
    Sep 30, 2018$0.81$0.79$0.74 - $0.83+2.53%Beat+22.7%8N/AOct 25, 2018$588.30M
    Jun 30, 2018$0.95$0.93$0.89 - $1.00+2.15%Beat+23.4%8N/AAug 2, 2018$623.63M
    Mar 31, 2018$0.92$0.86$0.79 - $0.91+6.98%Beat+29.6%6N/AApr 26, 2018$591.63M
    Dec 31, 2017$1.00$0.78$0.75 - $0.81+28.21%Beat+37.0%7N/AJan 22, 2018$601.27M
    Sep 30, 2017$0.66$0.66$0.63 - $0.690.00%In line+6.5%7N/AOct 26, 2017$523.66M
    Jun 30, 2017$0.77$0.74$0.70 - $0.78+4.05%Beat+4.1%9N/AAug 1, 2017$556.69M
    Mar 31, 2017$0.71$0.70N/A+1.43%Beat+4.4%N/AN/AApr 27, 2017$514.20M
    Dec 31, 2016$0.73$0.70N/A+4.29%Beat+5.8%N/AN/AJan 23, 2017$530.40M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Jun 30, 2026 was $11.17, up 17.0% from the year before. It was $2.83 for the year ended Jun 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Jun 30, 2026$11.17+17.0%
    Jun 30, 2025$9.55+23.5%
    Jun 30, 2024$7.73+19.8%
    Jun 30, 2023$6.45+11.4%
    Jun 30, 2022$5.79+8.6%
    Jun 30, 2021$5.33+12.0%
    Jun 30, 2020$4.76+30.4%
    Jun 30, 2019$3.65+3.4%
    Jun 30, 2018$3.53+24.7%
    Jun 30, 2017$2.83N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,800 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,80614
    2026Q2Jun 30, 20266,80010
    2026Q1Mar 31, 20267,58913
    2025Q4Dec 31, 20256,57412
    2025Q3Sep 30, 20258,92013
    2025Q2Jun 30, 20258,00914
    2025Q1Mar 31, 20259,83617
    2024Q4Dec 31, 20248,80615

    2026Q3 Earnings Call

    Opening remarks

    Sally Schwartz Chief Investor Relations Officer I want to welcome our listeners to ResMed Inc.'s third quarter fiscal year 2026 Earnings Call. We are live webcasting this call and the replay will be available on the Investor Relations section of our corporate website later today. Our earnings press release and presentation are both available online now. During today's call, we will discuss several non-GAAP measures we believe provide useful information for investors. This information is not intended to be considered in isolation or as a substitute for GAAP financial information. We encourage you to review the supporting schedules in today's earnings press release to reconcile these non-GAAP measures with the GAAP reported numbers. In addition, our discussion today will include forward-looking statements including, but not limited to, expectations about our future financial and operating performance. We make these statements based on reasonable assumptions; however, our actual results could differ. Please review our SEC filings for a complete discussion of risk factors that could cause our actual results to differ materially from any forward-looking statements made today. I will now turn the call over to Michael J. Farrell.

    Michael J. Farrell Chief Executive Officer (CEO) Thank you, Sally. Before we get into the details discussing our results for the quarter, I am sure all of you have had an opportunity to see our press release and our announcement that Brett will be retiring, and Aaron Blumer has been appointed our next chief financial officer here at ResMed Inc. On behalf of our ResMed Inc. Board and over 10 thousand ResMedians in 140 countries, I would like to thank Brett, who I have had the privilege to partner with for 26 years, including the last 55 quarters as a CEO and CFO team. Brett has been an integral part of my executive team that has delivered growth, expanded access, and improved hundreds of millions of lives. Over two decades as ResMed Inc.'s CFO, Brett has built a financial foundation that has allowed us to deliver strong growth, robust free cash flow, and best-in-class operating margins. Brett has also helped shape the company's culture, and his legacy is embedded in our impact on the lives of many millions of patients worldwide. Brett leaves ResMed Inc. in a position of strength with a very disciplined and global financial team. I am tremendously grateful to Brett for his service, his leadership, his friendship, and his commitment to ResMed Inc. I would also like to welcome Aaron Blumer to ResMed Inc. Aaron brings more than 17 years of global financial leadership, most recently serving as the CFO of Exact Sciences. He has a strong track record of driving strategic growth, operational excellence, and financial discipline across complex global organizations, including prior financial leadership roles at 3M and at Baxter.

    Frequently Asked Questions About RMD

    When is ResMed's next earnings date?

    ResMed's next earnings report is expected for Jan 27, 2027.

    Did RMD beat earnings estimates last quarter?

    Yes. ResMed reported EPS of $2.91 for the quarter ended Sep 30, 2026, above the $2.67 estimate, a 8.99% surprise.

    What EPS do analysts expect from RMD next quarter?

    The consensus EPS estimate for ResMed for the quarter ending Dec 31, 2026 is $2.99 from 13 analysts, with estimates from $2.93 to $3.13.

    How often does RMD beat earnings estimates?

    ResMed beat the EPS estimate in each of the last 13 quarters, with an average surprise of +4.15%.